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Mother-to-child transmission of chikungunya virus was 
reported during the 2005–2006 outbreak on Réunion Island, 
France. To determine the effects of this virus on pregnancy 
outcomes, we conducted a study of pregnant women in 
Réunion in 2006. The study population was composed of 
1,400 pregnant women (628 uninfected, 658 infected during 
pregnancy, 27 infected before pregnancy, and 87 infected 
on unknown dates). We compared pregnancy outcomes for 
655 (628 + 27) women not infected during pregnancy with 
658 who were infected during pregnancy. Infection occurred 
during the ﬁ  rst trimester for 15% of the infected women, the 
second for 59%, and the third for 26%. Only hospital admis-
sion during pregnancy differed between infected and unin-
fected women (40% vs. 29%). Other outcomes (cesarean 
deliveries, obstetric hemorrhaging, preterm births, stillbirths 
after 22 weeks, birthweight, congenital malformations, and 
newborn admissions) were similar. This virus had no ob-
servable effect on pregnancy outcomes.
C
hikungunya virus infection is transmitted by mosqui-
toes of the genus Aedes. The virus was ﬁ  rst isolated in 
1952 and is found in eastern Africa, India, and Southeast 
Asia. Symptoms of infection are high fever and disabling 
muscle and joint pain, often associated with a rash and 
mild bleeding. Persons infected usually recover spontane-
ously in several days to a week (1). Fever and arthralgia 
may occur for several months or even years (2). Patients are 
treated only for their symptoms because there is no speciﬁ  c 
treatment for the underlying infection (3). Before the recent 
outbreak on the island of Réunion, the disease was not con-
sidered life-threatening.
Réunion, a French territory in the southwestern Indian 
Ocean, has a population of ≈785,000 inhabitants. Medical 
facilities in Réunion are similar to those in mainland France 
and other industrialized countries. A major chikungunya 
outbreak occurred in Réunion in 2005–2006. At the end of 
this outbreak, seroprevalence was estimated to be 38.2% 
(95% conﬁ   dence interval [CI] 35.9%–40.6%); 300,000 
(95% CI 283,000–320,000) persons were infected (4,5). 
Aedes albopictus mosquitoes were the primary vector in 
this outbreak.
The outbreak began in eastern Africa (6). It reached 
Réunion in March 2005 but was relatively inactive, with 
only several thousand cases until November 2005, when 
its incidence unexpectedly increased during summer in the 
Southern Hemisphere, peaking at 47,000 cases/week dur-
ing week 5 of 2006. The most recent cases were reported 
in August 2006. Comparisons of 2006 with previous years 
showed that mortality rates increased during February, 
March, and April 2006 (7,8). Since 2006, the virus has 
caused several epidemics in the Indian Ocean region (Mad-
agascar, India, Sri Lanka, Thailand, Malaysia, and Singa-
pore). Three new cases of chikungunya were reported in 
August 2009 on Réunion Island (9).
The ﬁ  rst cases of virus transmission from mother to 
child at birth were identiﬁ  ed in February 2006; a total of 38 
such cases were reported (10,11). The virus was also found 
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in specimens from 3 early second trimester miscarriages 
(12). When this outbreak began, little information was 
available about the risk for chikungunya virus infection in 
pregnant women. In addition to virus transmission at birth, 
potential complications include transplacental transmission 
before birth, congenital malformations, stillbirths, growth 
restriction, and preterm delivery. Chikungunya virus be-
longs to the same family of viruses (Togaviridae) as rubella 
virus, for which some of these complications have been de-
scribed (13). The high fever that characterizes chikungu-
nya infection could cause uterine contractions or fetal heart 
rate abnormalities, which might promote spontaneous or 
induced preterm delivery (cesarean for fetal salvage). The 
hemorrhagic syndrome described at the onset of infection 
might be manifested by vaginal bleeding during pregnancy 
or third-stage hemorrhaging, as reported for infection with 
dengue virus (14,15). The proportion of symptomatic and 
asymptomatic infections was also unknown.
The purpose of our study (the Chikungunya-Mère-
Enfant cohort study) was to determine the consequences of 
chikungunya infection on pregnancy outcomes. These re-
sults will be useful to public health ofﬁ  cials and physicians 
who provide care for pregnant women or newborns because 
chikungunya can be imported by international travelers and 
the location of Ae. albopictus mosquitoes has extended be-
yond the tropics (16). These mosquitoes are found in 26 
states in the United States and several countries in Europe, 
where outbreaks are possible (17,18).
Methods
We began our study in early April 2006, by planning 
to recruit all pregnant women (with or without symptoms 
of chikungunya infection) who received care at 1 of the 6 
main maternity units in Réunion. These 6 units accounted 
for 78% of 14,077 live births in Réunion in 2006. Inclusion 
in the study was proposed regardless of the reason for a vis-
it or admission. We had planned to include 3,600 women so 
that sufﬁ  cient children with in utero chikungunya infection 
were available to study their psychomotor development. To 
show a difference of 10 points in the developmental quo-
tient at 24 months of age, it would have been necessary to 
observe 19 children infected in utero. However, because of 
the decrease in the outbreak after June 1, we revised our 
sample size and included only pregnant women who re-
ported clinical signs suggestive of this infection. The study 
cohort was composed of 1,400 pregnant women (mean 
term 32 weeks); 1,384 (99%) gave birth in 1 of the 6 partic-
ipating maternity units. Information on pregnancy outcome 
for 16 women lost to follow-up was obtained by contacting 
each one directly. A total of 914 participants were included 
in April, 386 in May, 88 in June, 5 in July, 2 in August, 4 in 
September, and 1 in November. In an ancillary study, for 3 
days in May 2006, all women who gave birth in the 6 par-
ticipating units were interviewed to determine how women 
in the study cohort differed from those not in the study in 
terms of chikungunya symptoms, parity, age, gestational 
age of the infant at birth, and mode of delivery.
Serologic status for chikungunya virus infection was 
determined at participant’s inclusion in the study. All re-
ports of chikungunya fever were conﬁ  rmed by using se-
rologic testing or detection of the viral genome in any 
specimen by using real-time reverse transcription–PCR 
(RT-PCR) (19,20). Serologic tests with negative results 
at inclusion were repeated at delivery or when symptoms 
suggestive of infection appeared. Histologic examinations 
were performed on placentas of all women who had chi-
kungunya infection during pregnancy. RT-PCR was also 
performed for placenta and amniotic ﬂ  uid samples from 
women with symptoms at delivery.
Date of infection was determined by checking patient 
history of symptoms or by RT-PCR when available. Wom-
en were classiﬁ  ed into 2 groups: those infected by chikun-
gunya virus during pregnancy (symptoms during pregnan-
cy conﬁ  rmed by positive serologic or RT-PCR results) and 
those not infected (negative serologic results at delivery 
or during the preceding 7 days). Women infected before 
pregnancy were considered not infected during pregnancy. 
We excluded women who were infected but asymptomatic, 
those whose symptoms could not be dated, and those with 
inconclusive serologic results from analysis.
We analyzed how women infected by chikungunya vi-
rus during pregnancy (658) differed from those who were 
not infected (655) for general characteristics (age, educa-
tional level, marital status, and body mass index), medical 
history (diabetes and hypertension), and obstetric history 
(previous pregnancies, history of preterm delivery, small-
for-gestational-age, or stillbirths). We then compared 
pregnancy outcomes (prenatal hospital admission for any 
reason and for chikungunya symptoms, vaginal bleeding 
during pregnancy, mode of delivery, obstetric hemorrhage, 
stillbirth, preterm birth, birthweight, congenital malforma-
tions, and newborn hospitalization) between the 2 groups. 
Obstetric hemorrhage was deﬁ  ned as blood loss >500 mL. 
We considered only fetal malformations recognized by Eu-
ropean Surveillance of Congenital Abnormalities (EURO-
CAT) (www.eurocat.ulster.antibodies.uk). All malforma-
tions recorded were veriﬁ  ed by checking either pediatric 
ﬁ  les or the Réunion congenital anomalies registry, which is 
afﬁ  liated with EUROCAT.
Bivariate analysis of pregnancy outcomes compared 
means (by Wilcoxon rank-sum test) and percentages (χ2 or 
Fisher exact tests). For multivariate analysis, we adjusted 
for center, maternal age, educational level, and body mass 
index. Logistic regression was used to estimate the ad-
justed odds ratios (ORs). A p value <0.05 was considered 
signiﬁ  cant. Sensitivity analyses were performed to deter-
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mine whether results changed when either the 27 infected 
before pregnancy or the 100 women included in the study 
after May 2006 were omitted from the analysis. Statistical 
analysis was performed by using SAS version 9.1 software 
(SAS Inc., Cary, NC, USA).
This prospective multicenter study was reviewed and 
approved by the ethics committee (Comité de Protection 
des Personnes) of Tours (no. 2006–2007). It was reported 
to the French Data Protection Authority (Commission Na-
tionale de l’Informatique et des Libertés). 
Results
Of 1,400 pregnant women included in the study, 705 
(50%) reported chikungunya symptoms during pregnancy, 
668 (48%) reported no symptoms, and 27 (2%) reported 
symptoms before pregnancy (Table 1). Speciﬁ  c serologic 
or RT-PCR tests conﬁ  rmed the diagnosis of chikungunya 
infection for 658 (93%) of 705 who reported symptoms 
during pregnancy. In 6 cases (1%), serologic results for 
immunoglobulin (Ig) G were negative at delivery, which 
ruled out infection. Conclusions could not be reached for 
41 women (6%) because of missing or inconclusive labora-
tory data. Negative serologic ﬁ  ndings for IgG conﬁ  rmed 
the absence of chikungunya infection in 622 (93%) of 668 
women with no reported symptoms during pregnancy. 
Findings were positive for 46 women (7%); these women 
were considered asymptomatically infected at an unknown 
date and excluded from the analysis. Chikungunya infec-
tion was conﬁ  rmed for all 27 women with symptoms before 
pregnancy. Overall, 658 women were classiﬁ  ed as infected 
by chikungunya virus during pregnancy (exposed) and 655 
as not infected during pregnancy (not exposed).
Among the 658 exposed women, infection occurred 
during the ﬁ  rst trimester for 99 (15%) women, the second 
for 387 (59%), and the third for 172 (26%). Infection oc-
curred during the ﬁ  rst quarter of 2006 for 536 (81%), before 
that for 62 (9.4%), and after that for 60 (9.1%). Maternal 
signs and symptoms were fever (408 cases, 62%), arthral-
gia (615 cases, 93%), headache (354 cases, 54%), edema 
(355 cases, 54%), diarrhea (78 cases, 12%), aphthae (63 
cases, 9.6%), epistaxis or gingivorrhagia (59 cases, 9.0%), 
and rash (496 cases, 76%). Overall, 137 (21%) were hos-
pitalized for chikungunya infection for a median duration 
of 2 days (range 1–75 days). Signs of infection began a 
median of 108 days before delivery (range 1–263 days), 
and only 4 infected women (0.6%) had symptoms in the 7 
days before delivery.
Pregnancy outcomes included 656 live births to women 
who were infected and 653 to those who were not infected 
(including 8 and 14 pairs of twins, respectively); 5 and 8, 
respectively, stillbirths after 22 weeks of gestation, and 5 
and 8, respectively, miscarriages before 22 weeks. Of the 
4 children born to mothers infected by chikungunya during 
the last week of pregnancy, 1 newborn had signs of infec-
tion on the third day of life, and RT-PCR and IgM sero-
logic analysis conﬁ  rmed the infection. The mother had had 
chikungunya symptoms the day before delivery. The other 
3 neonates remained asymptomatic and had no detectable 
IgM against chikungunya virus. Of 624 placentas examined 
from women found to be infected during pregnancy, only 
the placenta from the case of mother-to-child transmission 
had histologic signs compatible with viral infection.
RT-PCR was performed to test for the viral genome 
in the placenta or amniotic ﬂ  uid from 3 of the 5 stillbirth 
fetuses (>22 weeks) of women with chikungunya infec-
tions. The test result was positive in 2 cases, in which chi-
kungunya symptoms in the mothers had begun 25 and 70 
days before the fetal loss. For the 8 miscarriages before 22 
weeks, RT-PCR was performed on trophoblast tissue for 1 
case and the result was negative.
Women infected by chikungunya during pregnancy 
were more likely to have been born in Réunion, to have 
stopped going to school at a younger age, to be unmarried, 
overweight, or already have children (Table 2). They also 
differed by maternity center. Multivariate analysis showed 
that only 2 characteristics were signiﬁ  cantly different: edu-
cational level (primary school OR 1.48, 95% CI 1.11–1.97; 
high school as reference; university OR 0.54, 95% CI 0.38–
0.77) and being overweight (body mass index >25 kg/m2, 
OR 1.76, 95% CI 1.22–2.55).
After we controlled for potential confounders, the 
only difference in pregnancy characteristics between in-
fected and uninfected women (Table 3) was the frequency 
of hospital admissions during pregnancy (40% vs. 29%). 
This difference disappeared when hospital admission for 
suspected chikungunya was excluded (26% vs. 28%). 
Other maternal and neonatal outcomes were similar in 
both groups. Excluding women infected before pregnan-
cy or included after May 2006 from the analysis did not 
modify the results (Table 3). Congenital malformations 
observed in newborns as a function of maternal exposure 
are shown in Table 4.
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Table 1. Chikungunya virus infections in 1,400 pregnant women, 
by onset or lack of symptoms, Réunion, France, 2006* 
Symptoms No. infected Diagnosis
Symptoms during pregnancy, n = 705 
 Yes  658 Exposed
 No  6 Not  exposed 
 Unknown  41 Excluded
No symptoms, n = 668 
 Yes  46 Excluded
 No  622 Not  exposed 
Symptoms before pregnancy, n = 27 
 Yes  27 Not  exposed 
*Infection was confirmed by positive serologic or reverse transcription–
PCR results. Women infected before pregnancy were considered not 
infected during pregnancy. Chikungunya Virus during Pregnancy
In early May, we conducted a 3-day survey of all wom-
en giving birth in the maternity units participating in the 
study. Of 113 women interviewed, 43% (49) were included 
in the study cohort. The inclusion rate differed according to 
maternity unit, ranging from 16% to 88%. The mean pro-
portion of women asked to participate was 62% (70/113), 
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Table 2. Characteristics of women infected and not infected with chikungunya virus during pregnancy, Réunion, France, 2006* 
Characteristic Infected, no. (%), n = 658  Not infected, no. (%), n = 655  p value† 
Born in Réunion 
  Yes  545 (84.1)  510 (79.2) 
  No  103 (15.9)  134 (20.8)  0.02
Education
  Primary school  331 (52.2)  214 (34.3  <0.0001
  High school  198 (31.2)  200 (32.1) 
  University  105 (16.6)  209 (33.6) 
Marital status 
  Lives alone  252 (39.0)  207 (32.0)  0.008
  Lives with partner  394 (61.0)  440 (68.0) 
History of diabetes 
  Yes   17 (2.6)  14 (2.1) 
  No  641 (97.4)  641 (97.9)  0.59
History of hypertension 
  Yes  23 (3.5)  27 (4.1) 
  No  635 (96.5)  627 (95.9)  0.55
Previous pregnancies <22 wks 
 Yes  (>1)  273 (41.6)  258 (39.5) 
  No  384 (58.4)  395 (60.5)  0.45
Mean parity  1.4 (1.6)  1.1 (1.4)  <0.0001
  0  216 (32.9)  278 (42.7)  0.0004
  1  199 (30.3)  181 (27.8) 
  2  110 (16.8)  106 (16.3) 
>3 131 (20.0)  86 (3.2) 
Previous stillbirth or neonatal death 
  Yes  22 (3.3)  12 (1.8) 
  No  636 (96.7)  643 (98.2)  0.08
Previous preterm delivery 
  Yes  44 (6.7)  27 (4.1) 
  No  614 (93.3)  626 (95.9)  0.04
Previous child >2,500 g 
  Yes   70 (10.7)  55 (8.4) 
  No  587 (89.3)  598 (91.6)  0.17
Previous cesarean 
  Yes  71 (10.8)  66 (10.1) 
  No  587 (89.2)  586 (89.9)  0.69
Mean age at delivery, y  28.6 (6.9)  28.8 (6.4)  0.52
  <20  71 (10.8)  69 (10.5)  0.94
  20–29  309 (47.0)  303 (46.3) 
>30 278 (42.2)  283 (43.2) 
Mean body mass index, kg/m
2 24.7 (5.9)  23.4 (5.1)  <0.0001
  <25  390 (60.8)  454 (71.5)  <0.0001
  25–29  137 (21.3)  113 (17.8) 
>30 115 (17.9)  68 (10.7) 
Center
  1  165 (25.1)  188 (28.7)  <0.0001
  2  196 (29.8)  153 (23.4) 
  3  62 (9.4)  71 (10.8) 
  4  21 (3.2)  9 (1.4) 
  5  118 (17.9)  182 (27.8) 
  6  96 (14.6)  52 (7.9) 
*Women infected before pregnancy were considered not infected during pregnancy. 
†By Wilcoxon rank-sum test for continuous variables and Ȥ
2 test for nominal variables. RESEARCH
and the mean acceptance rate was 70% (49/70); 43% (21) 
of the women included thought that they had had chikun-
gunya infection during pregnancy compared with 6% (4) of 
those not included (p<0.0001). Mean parity (2.1 vs. 2.6; p 
= 0.08), mean maternal age (28.6 years vs. 29.1 years; p = 
0.70), mean gestational age at delivery (39.1 weeks vs. 38.7 
weeks; p = 0.14), and mode of delivery (18% vaginal vs. 
17% cesarean; p = 0.87) did not differ between the women 
who were or were not included.
Discussion
In this comparative study, we did not observe any ef-
fect of chikungynya infection on pregnancy outcomes ex-
cept for the number of prenatal maternal hospital admis-
sions for chikungunya symptoms. Our study involved a 
high proportion of maternity units and births in Réunion. 
Women included in the study in April 2006 accounted for 
73% (905/1,240) of all live births in Réunion. Systematic 
determination of serologic status by identiﬁ  cation of spe-
ciﬁ  c IgM and IgG conﬁ  rmed infection status. All patients 
for whom chikungunya infection during pregnancy was un-
certain were excluded. We excluded women who had posi-
tive serologic results but did not report symptoms or have 
a positive RT-PCR result because we could not identify the 
date of infection. Studies during the outbreak in Réunion 
showed that IgM tended to persist for 12 to 24 months and 
cannot be used to identify the date of infection (21).
Because inclusion in the study began in April 2006 after 
the outbreak had peaked, we could not analyze pregnancies 
completed before this date. Therefore, our study does not 
describe the consequences of the outbreak on the risk for 
miscarriage or preterm delivery during the ﬁ  rst quarter of 
2006. The study included only pregnancies with outcomes 
after that quarter. Most of the women were infected before 
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Table 3. Pregnancy outcome according to chikungunya virus infection during pregnancy, Réunion, France, 2006* 
Characteristic
Infected,†
no. (%), n = 658 
Not infected,‡ 
no. (%), n = 655  p value 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI) 
Hospital admission during pregnancy 
  Yes  266 (40.4)  191 (29.2)  1.65 (1.31–2.07)  1.52 (1.18–1.95) 
  No  392 (59.6)  464 (70.8)  <0.0001 1 1
Hospital admission during pregnancy, suspected infection with chikungunya virus excluded 
  Yes  180 (28.0)  136 (26.1)  0.91 (0.70–1.18)  0.83 (0.62–1.10) 
  No  464 (72.0)  385 (73.9)  0.48 1 1
Vaginal bleeding during pregnancy 
  Yes   55 (8.4)  68 (10.4)  0.79 (0.55–1.15)  0.94 (0.63–1.42) 
  No  596 (91.6)  584 (89.6)  0.22 1 1
Obstetric hemorrhaging 
  Yes  36 (5.6)  42 (6.5)  0.85 (0.54–1.35)  0.87 (0.53–1.42) 
  No  609 (94.4)  605 (93.5)  0.49 1 1
Mode of delivery§ 
  Vaginal  545 (83.8)  530 (81.5)  0.27 1 1
  Cesarean  105 (16.2)  120 (18.5)  0.85 (0.64–1.14)  0.77 (0.56–1.06) 
Mean gestational age, wk§  39.0 (2.1)  38.9 (2.5)  0.55
  <32  8 (1.2)  15 (2.3)  0.26 0.52 (0.22-1.24)  0.48 (0.19–1.23) 
  32–36  53 (8.2)  60 (9.2)  0.86 (0.59–1.27)  0.78 (0.51–1.20) 
>37 589 (90.6)  575 (88.5)  1 1
Mean birthweight, g§  3,116 (549)  3.056 (620)  0.27
  <2,000  20 (3.1)  32 (4.9)  0.36 0.62 (0.35–1.11)  0.66 (0.36–1.22) 
  2,000–2,999  235 (35.9)  236 (35.7)  0.99 (0.79–1.25)  1.01 (0.79–1.30) 
  3,000–3,999  372 (56.9)  371 (56.1)  1 1
>4,000 27 (4.1)  22 (3.3)  1.22 (0.69–2.19)  1.25 (0.65–2.39) 
Stillbirth after 22 wk§ 
  Yes  5 (0.8)  8 (1.2)  0.63 (0.20–1.93)  0.61 (0.18–2.07) 
  No  653 (99.2)  656 (98.8)  0.41 1 1
Congenital malformation 
  Yes  19 (2.9)  15 (2.2)  1.36 (0.68–2.74)  1.54 (0.68–3.49) 
  No  647 (97.1)  654 (97.8)  0.48 1 1
Admission to neonatal care§ 
  Yes  53 (8.1)  55 (8.3)  0.97 (0.65–1.44)  1.03 (0.67–1.58) 
  No  605 (91.9)  609 (91.7)  0.88 1 1
*OR, odds ratio; CI, confidence interval. OR was adjusted for center, educational level, body mass index, and maternal age. Women infected before 
pregnancy were considered not infected during pregnancy. 
†Of the 658 women who were infected, 650 had delivered a child after 22 weeks; 658 children were delivered by these women.  
‡Of the 655 women who were not infected, 650 had delivered a child after 22 weeks; 664 children were delivered by these women. 
§Miscarriage before 22 weeks was excluded. Chikungunya Virus during Pregnancy
their inclusion. The fact that many women seen in May had 
already been included at a previous visit in April explains 
why there were fewer inclusions in May; only pregnant 
women seen for the ﬁ  rst time or who for some reason had 
not been included in April were eligible. A disadvantage of 
conducting a study during an outbreak is that its duration 
cannot be known in advance. For this reason, the number of 
women was smaller than planned.
Date of infection was estimated by recording the time 
of symptoms and conﬁ  rmed by RT-PCR and serologic test-
ing. The positive predictive value of symptoms was reliable 
because infection was conﬁ  rmed in ≈93% of women with 
suggestive symptoms and ruled out in <1% of these wom-
en. The negative predictive value was also reliable because 
serologic results were negative for 93% of the women with-
out symptoms. These values are similar to the positive pre-
dictive value (91%) and negative predictive value (87%) of 
symptoms observed in a survey of a representative sample 
of the population in Réunion at the end of 2006 (4). These 
results conﬁ  rm that clinical signs of chikungunya have an 
excellent predictive value during an outbreak.
Women who thought that they had had chikungunya 
infection during their pregnancy because they had symp-
toms were more likely to agree to participate in the cohort 
than the women without such symptoms. There were also 
disparities in the inclusion rate according to maternity cen-
ter. Because of these differences, women included in this 
study were not representative of the population of pregnant 
women during this period in Réunion. These differences 
in the inclusion rate according to symptoms and hospital 
make it impossible to estimate the attack rate of infection 
among the population of pregnant women. However, be-
cause other characteristics (parity, age, gestational age at 
delivery, mode of delivery) were similar, sampling did not 
create any bias for comparisons between exposed and un-
exposed women.
The rarity of placental histologic lesions (in only 1 of 
624 women with chikungunya infection during pregnancy) 
conﬁ  rmed the absence of placental infection by the virus 
and explained the rarity of cases of fetal chikungunya infec-
tion before birth (22). Couderc et al. recently showed that 
human syncytiotrophoblast tissue is refractory to chikun-
gunya infection (23). During the outbreak in Réunion, only 
3 cases of fetal chikungunya infection at the beginning of 
the second trimester were reported (12). All other reported 
cases involved symptomatic newborns with chikungunya 
infection in the days after birth, for whom the presumed 
mechanism of viral transmission was direct passage from 
maternal blood into the fetal circulation through placental 
breaches during labor (11). Kwiek and others showed that 
maternal–fetal microtransfusions that occur during labor 
promote HIV-1 transmission from mother to child (24).
Our results are consistent with those of Gérardin et al., 
who showed that most cases of maternal–fetal transmission 
of chikungunya virus occurred at birth (22). Because we 
systematically determined chikungunya serologic status, 
we could compare pregnancy outcomes between infected 
and uninfected women. We found no difference in risk for 
hospitalization (except for suspected chikungunya), pre-
term delivery, low birthweight, or admission to neonatal 
care. However, the number of women tested enabled us 
to show a difference of 7% for prevalence of admission 
during pregnancy, 5% for preterm delivery, 82 g for fetal 
weight, and 5% for admission to neonatal care (β = 0.20 
and α = 0.05).
Stillbirths were not more frequent among women with 
chikungunya infection during pregnancy than among un-
infected women, even though >62% of infected women 
had fevers. This observation appears to conﬂ  ict with the 
hypothesis that fever plays a direct role in in utero deaths. 
However, because of the rarity of this event (0.64% in 2002 
in Réunion) (25), the power of the study is insufﬁ  cient to 
justify any deﬁ  nitive conclusion.
In our sample, the minimum detectable difference was 
1.8% for stillbirths (0.6% vs. 2.4%, β = 0.20 and α = 0.05). 
For early fetal loss before 22 weeks, the number of events 
(13/1,313 women) was lower than the number expected 
probably because most participants were included after that 
term. For this reason, we could not analyze outcome and 
reach a conclusion for this point.
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Table 4. Congenital malformation classification, according to ICD-10 code, as a function of maternal exposure to chikungunya virus 
during pregnancy, Réunion, France, 2006* 
Exposure to chikungunya virus during pregnancy,  
no. newborns, n = 34
Classification  Yes No 
Chromosomal (Q90, Q91, Q96)  3 1
Neural tube (Q03, Q05)  3 0
Cardiovascular (Q20, Q21, Q25, Q26)  5 1
Kidneys, urinary tract, genital organs (Q53, Q55, Q61, Q62, Q63)  1 5
Limbs, thorax, bones, and spine (Q66, Q69, Q71, Q74, Q76)  5 9
Ear, cleft palate (Q17, Q35)  3 0
Other (D22, Q33, Q40, Q42, Q89, T21)  4 3
*ICD-10, International Classification of Diseases, 10th revision. Total exceeds 34 because 1 child had 3 types of malformations and 7 children had 2 
types. RESEARCH
Chikungunya infection can also induce hemorrhagic 
complications (11). Overall, 59 infected mothers reported 
epistaxis or gingivorrhagia, but these symptoms are fre-
quent in pregnant women. We found no difference in the 
risk for vaginal bleeding during pregnancy or for third-
stage hemorrhage.
We observed more congenital malformations in babies 
exposed to chikungunya in utero than in unexposed babies 
(19 vs. 15). However, this difference was not signiﬁ  cant and 
we could not reach a deﬁ  nitive conclusion for this factor 
because only 99 women in our sample had a chikungunya 
infection during the ﬁ  rst trimester. It would have required 
1,340 children in each group to show a doubling of the risk 
(4% vs. 2%) with a power of 80% (β = 0.20 and α = 0.05). 
There is no information on long-term consequences of in 
utero exposure to chikungunya. Some newborns in our co-
hort were followed up until the age of 2 years. Analyses are 
underway to assess long-term consequences.
Chikungunya infection was more frequent in women 
with a lower educational level. That disadvantaged popu-
lations are overexposed to transmissible infectious dis-
eases, including dengue and chikungunya, has been shown 
(26,27). Therefore, during outbreaks, information and pro-
tection for all pregnant women should particularly be em-
phasized, especially for those whose educational level may 
result in a lack of basic knowledge about disease preven-
tion. It might be useful to screen these women actively and 
conduct home visits to verify application of basic antivector 
measures (destruction of mosquito breeding sites and larval 
havens around the home, wearing of long-sleeved clothing, 
and use of repellents appropriate for pregnant women and 
of mosquito netting).
The chikungunya vector (Ae. albopictus) is found in 
Asia, Oceania, North and South America, and Europe. In-
ternational travel creates the possibility of large-scale epi-
demics in countries previously considered free of chikun-
gunya (16,28). An epidemic of chikungunya was observed 
in a temperate zone (Italy) in 2007 (18). Our results will 
provide information for pregnant women in unimmunized 
populations during epidemics.
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